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N E U R O S C I E N C E
Iron is neurotoxic in retinal detachment and transferrin 
confers neuroprotection
Alejandra Daruich1,2,3, Quentin Le Rouzic1, Laurent Jonet1, Marie-Christine Naud1, 
Laura Kowalczuk2, Jean-Antoine Pournaras2, Jeffrey H. Boatright4,5, Aurélien Thomas6,7, 
Natacha Turck7,8, Alexandre Moulin2, Francine Behar-Cohen1,7,9*†, Emilie Picard1*
In retinal detachment (RD), photoreceptor death and permanent vision loss are caused by neurosensory retina 
separating from the retinal pigment epithelium because of subretinal fluid (SRF), and successful surgical reattach-
ment is not predictive of total visual recovery. As retinal iron overload exacerbates cell death in retinal diseases, 
we assessed iron as a predictive marker and therapeutic target for RD. In the vitreous and SRF from patients with 
RD, we measured increased iron and transferrin (TF) saturation that is correlated with poor visual recovery. In 
ex vivo and in vivo RD models, iron induces immediate necrosis and delayed apoptosis. We demonstrate that TF 
decreases both apoptosis and necroptosis induced by RD, and using RNA sequencing, pathways mediating the 
neuroprotective effects of TF are identified. Since toxic iron accumulates in RD, we propose TF supplementation 
as an adjunctive therapy to surgery for improving the visual outcomes of patients with RD.
INTRODUCTION
Retinal detachment (RD) is an ocular emergency, as separation of the 
neuroretina from the underlying retinal pigment epithelium (RPE) 
(Fig. 1A, arrowhead) disturbs photoreceptor (PR) metabolism, causing 
PR death and subsequent vision loss (1). In rhegmatogenous retinal 
detachment (RRD), a retinal tear (Fig. 1A, arrowhead) induces sub-
retinal fluid (SRF) accumulation in a space formed between the neu-
roretina and the RPE. The incidence of adult RRD varies between 
10 and 55 per 100,000 individuals per year, with higher occurrence 
in patients who also have myopia or pseudophakia (2). This incidence 
will likely rise with myopia increasing worldwide (3). Intraocular 
surgery is commonly used to repair RRD but must be realized rap-
idly after detachment, as the duration of macular detachment is one 
of the major visual prognosis factors (4). The principles of surgery 
are based on retinal break closure (i.e., by laser therapy or cryother-
apy) and internal or external temporary tamponade to maintain the 
retina attached during wound healing. When the procedure is per-
formed internally, vitreous is removed and SRF is eventually extracted. 
Despite tremendous progress made in surgical techniques and the 
high repair rate, 60% of patients with RRD involving the macula 
(macula-OFF RD, 50% of the cases) recover less than 20/40 vision 
(4) and have poor vision-related quality of life (5). Improving vision 
after RD surgery is thus a critical therapeutic challenge.
Experimental models of RD correlate well with human pathology, 
making them appropriate to study mechanisms and pharmacothera-
peutic strategies. First changes are observed at the RPE/PR interface 
(6), followed by PR cell death that peaks at 2 to 3 days through apop-
tosis, necrosis, and autophagic cell death mechanisms (1). Caspase 
inhibitors do not prevent cell death in RRD models but rather pro-
mote receptor-interacting protein (RIP) kinase–dependent necrosis, 
referred to as necroptosis (7). Subsequent inflammatory reactions, 
including macrophage/microglial activation, contribute to a neuro-
toxic environment and to subsequent gliosis (8). Factors initiating 
cell death during RD remain undetermined, and the identification 
of a common target of the different death mechanisms is mandatory 
for developing an effective neuroprotective strategy for RD.
Iron is an important biological component for catalyzing enzy-
matic reactions, but when it is poorly liganded, iron generates reactive 
oxygen species, damaging cellular components (9). Iron-mediated 
retinal cell death has been suspected to occur in various forms of 
retinal degeneration (10), including age-related macular degeneration 
(AMD) (10), the leading cause of blindness in developed countries, 
but no correlation between iron and visual function was possible, and 
the iron sequestration capacity in human ocular fluids has never been 
evaluated in relation to retinal diseases. The control of ocular iron 
homeostasis is tightly controlled by retinal cell proteins, and the iron 
transporter, transferrin (TF), is one major protein found in the vit-
reous. We previously showed that the sequestration of two ferric iron 
ions by TF (11) prevents the formation of free radical–mediated 
stress and glial retinal cell death in culture. Our previous studies also 
showed, in various animal models, that treatment with TF exerted 
retinal neuroprotective effects through the reduction of apoptosis, 
inflammation, and oxidative stress (12, 13). However, the molecular 
mediators and pathways involved in the protective effects of TF have 
never been investigated in depth.
In our study, we evaluated the iron and TF status in ocular fluids 
from patients with RRD and correlated those parameters to visual 
acuity recovery and duration of RRD. Retinal explants are a com-
mon tool used for RD studies, recapitulating pathological processes 
found in the detached retina (14). Thus, we established an ex vivo 
model of RRD by placing rodent retinas under iron overload cul-
ture conditions and investigated whether TF protects the retina by 
evaluating apoptosis, necroptosis, and oxidative stress cell markers. 
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Fig. 1. Iron accumulates during RD in humans. (A) Schematic representation of RRD. RPE strictly interacted with PRs (rods and cones), supporting their function and 
maintaining retinal physiology. During RRD, separation of the neural retina from the RPE disrupts the metabolism of PRs and induces permanent cellular damage, SRF 
accumulation through the retinal tear (arrowhead), and inflammatory cells in subretinal space. (B to D) Iron level (B), total iron binding capacity (TIBC) (C), and transferrin 
saturation (TSAT) (D) were quantified in vitreous from control patients and in vitreous and SRF from patients with RRD. Unpaired t test (n = 9 to 35 for vitreous and n = 30 
for SRF), *P = 0.046 and **P = 0.006. ns, not significant. (E) Iron level in SRF was correlated to duration of the RRD (n = 30) and to the visual recovery 1 month following 
surgical treatment (n = 10). Pearson correlation test, *P < 0.05. (F) Perl’s staining (blue) on retinal sections from patients with nonhemorrhagic RD (asterisk shows space 
between retina and underlying RPE) revealed iron deposits in the retina and the RPE (arrows). Scale bars, 500 m. (G) Iron distribution map realized by inductively coupled 
plasma mass spectrometry (ICP-MS) on the retina from a patient with nonhemorrhagic RD revealed iron deposits (arrowheads). An optical image of the analyzed retina 
section (left), the corresponding ICP-MS image of Fe distribution (medium), and the superposition of both (right). The color spectrum represents an ion intensity map of 
Fe. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; m/z, mass/charge ratio; ppm, parts per million. All values are represented as the mean ± SEM.
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Transgenic mice expressing human TF (hTF) in the retina were 
used to observe TF neuroprotective efficiency in an experimen-
tally induced RD model (15), and an RNA sequencing (RNA-seq) 
approach was used to explore the pathways implied in these ef-
fects. Intravitreal injection of TF in rats following experimental 
RD was used to determine the potential of TF as an adjuvant for 
RD surgery.
RESULTS
In ocular fluids from patients with RRD, iron increases  
with detachment duration and correlates with poor  
visual recovery
Total iron, TF, total iron binding capacity (TIBC), and percentage 
of transferrin saturation (TSAT) were evaluated in undiluted vitre-
ous and SRF collected from patients with RRD (age, 64.3 years; SD, 
9.6; 11 females and 24 males; n = 35) and from control patients (age, 
70.2 years; SD, 9.5; 5 females and 4 males; n = 9). In the vitreous, the 
level of iron was significantly higher in patients with RRD as com-
pared to control subjects without RD (143.1 ± 14.4 ng/ml versus 
81.7 ± 16.8 ng/ml; P = 0.046) (Fig. 1B). The TIBC values did not 
differ in eyes with or without RRD (4.5 ± 0.7 and 4.3 ± 0.6 M TF; 
P > 0.5), but TSAT increased from 22.8 ± 3.8% in control eyes to 
89.91 ± 11.4% in eyes with RRD, reaching almost complete satura-
tion (P = 0.006; Fig. 1, C and D). In the SRF, the high rate of TSAT 
(53.5 ± 12.6%) (Fig. 1D) also reflected iron overload. Higher levels 
of iron in the SRF were associated with longer duration of detach-
ment (P = 0.038; Fig. 1E, left graph) and correlated with lower visual 
recovery 1 month after surgery (P = 0.047; Fig. 1E, right graph). Be-
cause the data are correlative, these results suggest that iron toxicity 
could contribute to the functional outcome in RRD.
Iron deposits, evaluated in postmortem ocular tissue sections of 
RD, were found in the remaining PR layer, inside cells in the subreti-
nal space that are very likely to be inflammatory cells (arrows), and 
in RPE (Fig. 1F) using Perl’s staining. Inductively coupled plasma 
mass spectrometry (ICP-MS) analysis confirmed elevated iron 
content throughout the retina sections (Fig. 1G, green), with high-
er concentrations in focal areas (red, arrowheads). These observa-
tions suggest that iron could mediate, at least partially, PR damage 
during RRD.
Iron induces PR death in rat retinal explants ex vivo
To evaluate iron neurotoxicity, rat neural retina explants were cul-
tured in low-serum medium, and PR cells were immediately exposed 
to iron at a range of concentrations similar to those measured in SRF 
from patients with RRD. After 2 days of exposure to 1 mM FeSO4 
(fig. S1A), no increase in caspase-dependent apoptosis was observed 
[caspase 3 activation and TUNEL (terminal deoxynucleotidyl transferase– 
mediated deoxyuridine triphosphate nick end labeling)–positive cells 
were similar under control and iron conditions] (fig. S1, B and C). 
However, lactate dehydrogenase (LDH) release, an early marker of 
necrosis, was concentration- dependently increased as early as 1 day 
after iron overload exposure (fig. S1D). After 2 days of iron over-
load, necroptosis was confirmed with an increase of RIP kinase pro-
tein expression and staining of PR nuclei with propidium iodide 
(fig. S1, E and F). The 2 days of iron exposure led to the loss of both 
rod and cone PRs, as shown by the decreased rhodopsin protein 
level with increasing concentration of FeSO4 (Fig. 2B) and nearly 
no arrestin-positive cones remaining after 1 mM FeSO4 exposure 
(Fig. 2C, arrows). After iron overload, progressive histological dam-
age appeared over time, leading to complete retinal layer disorgani-
zation and shortening of the residual PR segments (Fig. 2D), iron 
diffusely stained the retinal explants 7 days after iron removal, 
particularly in the remaining PR segments, and was concentrated 
in inflammatory cell types (brown, arrows), as observed in human 
RD sections (Fig. 2E). The direct contact of iron with PR led to 
immediate necroptosis that increased with higher iron concen-
trations and with longer iron exposure times.
TF protects against iron-induced toxicity in ex vivo mouse 
and rat retinal explants
In transgenic (TG) mice expressing hTF in retinal cells (11), hTF 
levels increased in the medium with the duration of retinal explant 
culture (fig. S2, A to C). TG-derived explants exhibited fewer signs 
of degeneration and oxidative stress in low-serum medium com-
pared with wild-type (WT) explants. After 6 days of culture, retinal 
glial Müller cell activation, identified by glial fibrillary acidic protein 
(GFAP) distribution (fig. S2D, arrow) (16), and markers of oxida-
tive stress [8-hydroxyguanosine (8-HGN) and 4-hydroxynonenal 
(4-HNE)] (fig. S2, E and F) were reduced in retinal explants from 
TG mice compared with those from WT mice.
Subsequently, we investigated whether TF was protective against 
iron overload combined with RD. Iron overload conditions were ap-
plied to TG and WT retinal explants (Fig. 3A). LDH release, evalu-
ated after 1 day, was reduced by 24.4% in retinal explants from TG 
mice as compared with explants from WT mice (P = 0.03; Fig. 3B). 
After 6 days of iron exposure, the number of cones was 55.5% higher 
and the outer segment (OS) lengths were 58.2% longer in retinas 
from TG mice as compared with WT (P < 0.0001 for both; Fig. 3C). 
In addition, reduced Müller glial cell activation and oxidative stress 
markers (fig. S3, A to C) were observed in retinal explants from TG 
mice. The expression of hTF in TG mice retinas reduced iron accu-
mulation as indicated by a reduction in ferritin light chain (LFt) 
staining (Fig. 3D) (12). The TG mouse retinas were thus protected 
from iron-induced oxidative stress and necroptosis.
We then evaluated the effect of TF added to rat retinal explants 
after 2 days of iron exposure to more closely mimic the therapeutic 
time course common in human RD treatment. After 2 days, iron 
was removed and exogenous hTF (50 mg/ml) was added in the me-
dium (Fig. 3E). TF treatment rescued not only rod-specific protein 
[61.7% greater rhodopsin level (P = 0.021); Fig. 3F] and the lengths 
of rod OSs (Fig. 3G, asterisk) but also cones [83.8% greater number 
of cones versus untreated (P = 0.04); Fig. 3G, arrows]. Two days after 
iron exposure, the RIP kinase protein level remained elevated, but 
the presence of the cleaved form of RIP kinase proteins (Fig. 3H) 
suggested an activation of caspase 8, leading to a delayed activation 
of apoptosis (7). Treatment with hTF significantly reduced the level 
of cleaved RIP kinase by 76.1% (P = 0.028; Fig. 3H), increased the 
antiapoptotic protein Bcl2 by 83.3% (P = 0.028; Fig. 3I), and reduced 
the number of TUNEL-positive cells (Fig. 3J). As expected, LFt stain-
ing intensity was reduced (Fig. 3K), in parallel to the reduction of 
iron deposits in the retina. Exogenous hTF prevented the activation of 
resident macrophages/microglial cells (fig. S4A, CD68, arrowheads) 
and decreased Müller glial cell activation (fig. S4B, GFAP, arrows). 
The iron-induced oxidative stress markers 4-HNE and 8-HGN were 
also decreased with hTF treatment (fig. S4, C and D). Together, 
these results demonstrate that treatment with exogenous TF effi-
ciently protects the retina from two types of iron-induced toxicity: 
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direct and early necroptosis and delayed apoptosis that could result 
from secondary iron-related effects.
TF rescues the detached mouse retina in vivo
We induced partial RD in mice and rats (about 50 to 70% and 30 to 
50% of the retinal surface, respectively). After 7 days, the detached 
retina was thickened, the outer nuclear layer (ONL) was disorga-
nized, PR nuclei were pyknotic, OSs were absent, and RPE cells 
were enlarged in the detached area (fig. S5). Similar to human RD, 
iron accumulated in the detached rodent outer retinas (fig. S6, A 
and B) and in rat ocular fluids (52.54% increase in total iron levels 
after 14  days of detachment; P  =  0.042) (fig. S6C). In TG mice 
(Fig. 4), hTF protected the detached retina from edematous thick-
ening [21.7% decrease in retinal thickness of the detached retina/
nondetached retina (P = 0.045), designated by brackets in Fig. 4A 
and quantified in the left graph of Fig. 4B] and from ONL thinning 
[20.3% decrease (P = 0.033); Fig. 4B, right graph] and prevented PR 
OS shortening [50% decrease (P = 0.047); graph in Fig. 4C and ar-
rowheads in Fig. 4 (A and C)]. TG-detached retinas had 311.3% more 
cones than WT (P = 0.025; Fig. 4D). Activation of Müller glial cells 
was significantly reduced in TG mouse retinas (Fig.  4E, arrows). 
Compared with WT retinas, hTF expressed in TG retinas decreased 
caspase 8 mRNA expression by 48.9% (P = 0.008), the level of the 
cleaved form of caspase 3 protein by 57.1% (P = 0.03), and the num-
ber of TUNEL- positive cells in the ONL of detached retinas by 56.3% 
(P = 0.03), demonstrating the antiapoptotic effect of TF in the mouse 
RD model (Fig. 4F). RIP kinase protein levels were reduced by 35.4% 
in the TG-detached retina compared with the WT (P = 0.03) (Fig. 4G), 
suggesting that hTF reduced both apoptotic and necrotic cell death in 
the mouse RD model.
Molecular signature of hTF overexpression in the  
mouse RD model
We performed a genome-wide analysis (RNA-seq) of neural retinas 
from TG and WT mice 4 days after induction of RD. From a total of 
412 genes differentially regulated between TG and WT mice (1.5-fold 
change; P ≤ 0.05), 149 were up-regulated and 263 were down-regulated. 
An extensive list is provided in data file S1. The 20 most up- and 
down-regulated genes are listed in table S1. Gene ontology (GO) 
(biological process, molecular function, and cellular compartment 
Fig. 2. Iron toxicity for PRs in rat retinal explants. (A) Illustration of the retinal explant model and the timed workflow for iron exposure protocol: Adult rat retinas were 
dissected, placed on membranes with PRs facing up, and immediately exposed for 2 days to iron (FeSO4). Control explants were cultured with medium alone. Some ex-
plants were harvested, and Western blotting and immunostaining were performed. Afterward, the medium was completely replaced, and explants were maintained in 
culture for 4 or 7 days for histological analysis and iron staining, respectively. (B) Western blotting and quantitative analysis of a rod protein showed a decreased rho-
dopsin level in explants exposed to increasing concentrations of FeSO4. The molecular masses of the immunolabeled fragments were indicated in the right margin. 
Mann-Whitney test (n = 3, *P = 0.028). (C) Immunostaining of arrestin (red, arrows) and subsequent quantification showed very few cones present in explants exposed to 
1 mM FeSO4. Mann-Whitney test (n = 3, ***P < 0.0001). (D) Semithin sections of explants showed disorganization of the ONL and segments after 1 mM FeSO4 exposure. 
(E) 3,3′-Diaminobenzidine (DAB) amplified Perl’s reaction revealed iron deposits (arrows) in explants exposed to 1 mM FeSO4. GCL, ganglion cell layer; ONL, outer nuclear 
layer; INL, inner nuclear layer; S, segments. Scale bars, 100 m. All values are represented as the mean ± SEM.
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categories) and reactome pathway enrichment analysis demon-
strated significantly affected categories in genes down-regulated or 
up-regulated in TG mice as compared with WT (Fig. 5; see data file S1 
for details). We regrouped the significantly enriched pathways into 
10 groups according to their biological functions: retina homeostasis, 
neurological process, phagocytosis, immune system, remodeling of 
extracellular matrix (ECM), mechanisms of cell death, metabolism, 
DNA/RNA regulation, intracellular signaling, and others, which com-
prise other biological functions such as cellular proliferation and 
differentiation (Fig. 5). The retina homeostasis group was solely 
composed with the most significantly enriched GO term “photore-
ceptor cell maintenance,” which included genes related to the con-
nector cilium linking the inner segment (IS) to the OS and playing 
a major role in rhodopsin transport toward OS disks. Pathways 
Fig. 3. Expression of TF protects retina explants exposed to iron. (A) Illustration of timed workflow for retinal explants from WT and TG mice expressing hTF continu-
ously exposed to 1 mM FeSO4. LDH release was measured after 1 day and immunostaining after 6 days. (B) LDH release was lower in culture medium from TG explanted 
mice compared to WT explants. Mann-Whitney test (n = 6), *P = 0.03. (C) Number of cones stained by arrestin (arrow) and length of rod segments stained by rhodopsin 
(Rho4D2) were quantified and were higher in TG explants. Mann-Whitney test (n = 3), ***P < 0.001. (D) Quantification of immunostaining intensity for markers of iron 
storage LFt was decreased in TG explants compared with WT explants. Mann-Whitney test (n = 3), **P < 0.01. (E) Illustration of timed workflow for TF treatment on 
iron-exposed explants: Adult rat retinas were exposed for 2 days with 1 mM FeSO4. Control explants were cultured with medium alone. Afterward, the medium was 
completely replaced and explants were treated with hTF (50 mg/ml) for 2 or 4 days. (F) Quantitative analysis of rhodopsin protein by Western blotting show increased 
rhodopsin protein expression in TF-treated iron-exposed explants (Fe + TF). Mann-Whitney test (n = 3), *P = 0.021. (G) Rhodopsin and arrestin immunostaining revealed 
protection of rod segments (Rho4D2, asterisk) and cones (arrow) by TF treatment (Fe + TF). Quantification of cone nuclei showed more cones in explants treated with TF 
than those exposed to FeSO4. Mann-Whitney test (n = 3), *P = 0.036. (H) Western blotting and quantitative analysis of RIP kinase demonstrated higher full form and 
cleaved form of the proteins in iron-exposed retinal explants. The cleaved form of RIP reported on RIP full form was reduced when TF was used to treat iron-exposed ex-
plants. Mann-Whitney test (n = 3), *P = 0.028. (I) Antiapoptotic Bcl2 protein, detected by Western blotting, was increased in TF-treated iron-exposed explants. Mann-Whitney 
test (n = 3), *P = 0.028. (J) TUNEL-positive cells in the ONL were reduced by TF treatment. (K) Immunostaining of iron storage marker ferritin light chain was significantly 
lower in explants treated with TF (Fe + TF) than without treatment (Fe). Fluorescence intensity was reported relative to control conditions. One-way analysis of variance 
(ANOVA), Bonferroni post test (n = 3), *P < 0.05. Scale bars, 100 m. All values are represented as mean ± SEM.
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relative to the neurological process group were especially involved 
in the regulation of neuron development and cognition. The phago-
cytosis group was composed of the most significant biological process 
according to the reactome analysis (“endoplasmic reticulum– 
phagosome pathway”) that was also represented in GO analysis as-
sociated with the “receptor-mediated endocytosis” and the “regulation 
of vesicle fusion” pathways. The GO molecular function analysis re-
vealed that “binding” was the most significantly enriched term (16 
of a total of 29 terms) (data file S1). Furthermore, of the top 20 up- 
and down- regulated genes, half were associated with “protein bind-
ing” molecular function (GO term classification) (table S1). Pathways 
regrouped in the immune system group were also highly represented 
in the two enrichment analyses, and genes included in those were 
mostly up- regulated. Pathways related to the mechanism of cell 
death group were represented by two GO biological process terms 
involved in the regulation of apoptotic processes. In the 40 most 
significantly regulated genes, 12 were implied in cell death process-
es (table S1). The GO analysis of the cellular components showed 19 
significant enrichments, which can be regrouped into three equal 
cellular compartments: the nucleus, the cytoplasm, and membranes 
(data file S1), reflecting cross-talk between the cell membrane and 
the nucleus.
Fig. 4. TF expression preserves the detached retina in mice. (A) Semithin retinal sections from control WT mice without RD and WT and TG mice expressing hTF 7 days 
after RD (red asterisks). In TG mice, the histology of the detached retina (brackets) was less disrupted than in WT mice, with remaining OS (arrowheads). Nuclei were stained 
with toluidine blue. Measurements of total retinal thickness in the detached area were reported to undetached retina thickness. (B) Expression of hTF in mice (TG) reduced 
thickening of the total retina and ONL. Mann-Whitney test (n = 5), *P < 0.05. (C) Rhodopsin staining in OS was conserved in TG compared with WT mice (arrowheads) 
7 days after RD. The length of OS measured on semithin sections was higher in TG mice compared with WT mice. Mann-Whitney test (n = 6), *P = 0.047 (D) Arrestin staining 
revealed cones in retinal sections of TG mice (arrows) 7 days after RD. Cone number was higher in TG compared with WT mice. Mann-Whitney test (n = 6), *P = 0.025. 
(E) Müller glial cell activation revealed by GFAP expression was lower in TG mice compared with WT mice (arrows). Mann-Whitney test (n = 5), **P = 0.0056. (F) Cellular markers 
of apoptosis were lower in TG compared to WT mouse retinas. Caspase 8 mRNA level by reverse transcription quantitative polymerase chain reaction (RT-qPCR), and the 
ratio of cleaved/pro–caspase 3 protein levels was determined by Western blotting performed 4 days after RD. TUNEL staining was performed in eyes collected 7 days after 
RD. Mann-Whitney test (n = 5), **P = 0.008 and *P = 0.028. (G) Necrotic RIP kinase protein level, detected by Western blotting, was reduced in TG mice compared with WT 
mice. Mann-Whitney test (n = 3), *P = 0.028. IS, inner segment. Scale bars, 100 m (A, E, and F) and 50 m (C and D). All values are represented as the mean ± SEM.
Daruich et al., Sci. Adv. 2019; 5 : eaau9940     9 January 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
7 of 14
Among the 412 genes differentially regulated between TG and 
WT mice, 2 genes (Tfrc and Igfbp3) encode proteins with direct inter-
actions with TF (17). The insulin-like growth factor binding protein 3 
(Igf bp3) transcript was significantly increased in TG mouse retina 
compared with WT 4 days after RD induction (fold change: 3.27, 
P = 0.086; table S1). In the normal retina, the IGFBP3 protein was 
localized in PR segments (arrowhead) in retinal capillaries and in the 
outer plexiform layer (arrow) (fig. S7A). Western blot analysis con-
firmed an increase of 46.7% of IGFBP3 protein level in the retinas of TG 
mice compared with WT mice 7 days after RD (P = 0.028; fig. S7B).
Local ocular injection of TF preserves detached  
rat retinas in vivo
In a therapeutic perspective trial, intravitreous injection of hTF 
(50 mg/ml) showed protective effects in a rat RD model (Fig. 6A). The 
retinal thickness of the detached retina/nondetached retina (Fig. 6A, 
Fig. 5. High-throughput analyses of the transcriptome of TG mouse retinas following RD. Overrepresentation pathway analysis using GO terms enrichment (biolog-
ical process clustering) (A) and reactome biosource (B). Color codes were used to associate pathways with common biological effects. Comparative analyses were carried 
out in TG versus WT retinas 4 days after RD (n = 4). GO terms and pathways were considered as enriched if fold enrichment is ≥2.0, uncorrected P value is ≤0.05, and the 
minimum number of regulated genes in pathway/term is ≥2.0. MHC, major histocompatibility complex; ER, endoplasmic reticulum.
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brackets, and Fig 6B, upper graph) was 14.2% lower in TF-treated 
rats (P = 0.003), whereas the ONL thickness was preserved [30.6% 
reduction (P = 0.013); Fig. 6B, middle graph], and immunostaining 
of rod and cone PRs (Fig. 6C) revealed preserved morphology. 
There was a 37.6% reduction of OS length (Fig. 6, B and C, arrow-
head) in balanced salt solution (BSS) RD rats compared to TF-treated 
rats (P = 0.004; Fig. 6B, lower graph). Therapeutic TF thus reduced 
edema of the detached retina and preserved PR morphology. To-
gether, these results indicate that TF, even if administrated at the 
time of RD, can prevent further retinal alterations and cell death.
DISCUSSION
Iron accumulation–induced oxidative stress has been observed in 
neurodegenerative and retinal diseases (9) and causes rapid PR death 
(10), but no correlation between intraocular iron and visual func-
tion has been demonstrated in a human disease. In our study, we 
show in human eyes increased iron levels and TSAT in the vitreous 
and SRF fluid, reflecting the accumulation of free iron in ocular tis-
sues (RPE, PRs, and inflammatory cell–like) upon RD. Our results 
confirmed previous analyses that demonstrate increased oxidative 
stress in vitreous from patients with RRD (18).
Increased iron following RD could result from a combination of 
factors. In physiologic conditions, retinal iron entry is actively con-
trolled through TF uptake by its receptor at the RPE basal mem-
brane that forms the outer retinal barrier. After detachment, acute 
RPE alteration (6) may favor free iron entry. Similarly, a breakdown 
of the inner blood-retinal barrier in an animal model of type 2 mac-
ular telangiectasia, a rare human disease, led to iron accumulation 
in the retina and PR degeneration (19). However, iron accumulation 
was also shown in retinal dystrophies, especially in PRs, without ob-
vious barrier breakdowns (20), suggesting that other mechanisms 
contribute to iron increases. PRs and RPE have high iron content 
because iron is a cofactor in phototransduction enzymes and have a 
major role in iron retinal homeostasis by the synthesis of TF (20). 
RPE cells, through the phagocytosis of shed OSs, recycle iron and 
export it from the retina (20). During RD, the loss of contact between 
PR and RPE leads to intracellular iron accumulation, a mechanism 
described in the Royal College of Surgeons (RCS) dystrophic rat, a 
genetic model of defective OS phagocytosis (20). PRs are extremely 
sensitive to iron excess, but the exact mechanisms of this toxicity 
have not been fully determined. We used organotypic retinal cul-
tures to show that direct contact with iron causes rapid PR necrosis. 
Peroxidation by iron of polyunsaturated fatty acids in the OSs could 
be one necrotic mechanism (21). Furthermore, when iron has accu-
mulated in the retina explant and after its removal from medium, 
apoptotic cell death observed could result from intracellular molecu-
lar iron- induced oxidation through the Fenton/ Haber-Weiss reac-
tion cycle (DNA, RNA, lipids, and proteins) (9), as suggested by DNA 
breaks (8-HGN) and lipid peroxidation (4-HNE) (fig. S4). Thus, labile 
iron exerts deleterious extracellular and delayed intracellular effects. 
The fact that vision recovery in patients with RRD was inversely cor-
related with ocular iron levels suggests that iron toxicity could be one 
of the mechanisms of PR loss over the time course of RRD.
The observed fully saturated TF in ocular fluids and intracellular 
iron accumulation in the retina suggest that iron loading capacities 
are saturated. Therefore, the use of TF appears as a relevant thera-
peutic therapy. Chemical chelators (deferiprone, deferoxamine, or 
deferasirox) have already been evaluated in neurogenerative diseases 
after systemic administration (22). However, long-term iron chela-
tion therapy, routinely used for instance in beta-thalassemia and 
chronic iron overload diseases, negatively affects patient’s quality of 
life and induced ocular toxicity, including cataracts, maculopathy, 
and optic neuritis (23, 24). Thus, the use of these chemical chelators 
in patients with RD without systemic iron overload could be delete-
rious for the eye. Moreover, intraocular local administration of 
chemical iron chelators would require repeated intravitreal injec-
tions due to their short half-life (25). Such local administration 
might cause excessive intracellular iron depletion due to the high 
chelator-to-iron ratio.
On the basis of these findings, we proposed to use local ocular 
TF to neutralize iron toxicity. We previously showed that TF is safe 
for ocular use even at high doses and prevents iron accumulation 
in RPE and PRs, and that iron-loaded (holoTF) and iron-free TF 
egresses the retina through the TF receptor at the RPE apical side 
(12). Using various models of retinal degeneration, we have previ-
ously showed that apoTF has a neuroprotective effect (12, 13), but 
involved mechanisms have not been yet fully elucidated. Here, using 
two RD models, we confirmed that apoTF efficiently removes iron 
and exerts antioxidant and neuroprotective effects. However, recent 
studies have demonstrated that the blockade of apoptosis or necro-
ptosis was required to protect the detached retina (7). Using TG mice 
that express hTF in the retina or using therapeutic regimens with 
exogenous TF, we demonstrated that TF reduced both the direct 
iron-mediated necroptosis through RIP kinase down-regulation 
and the delayed iron-induced apoptosis.
The biological effects of TF, present at high concentration in the 
normal vitreous, are not limited to iron metabolism, and the neuro-
protective properties of TF result from numerous targeted pathways. 
Lesnikov et al. (26) previously demonstrated that upon binding to 
TF receptor 2 (TFR2), TF protected against Fas-induced cell death 
via the mitochondrial pathway by reducing BID cleavage, inhibiting 
caspase 3 and caspase 9 activations, and up-regulating survival 
signals such as Bcl-xL. The retinal transcriptome of TG RD mice 
compared with WT RD mice highlighted seven major groups of 
pathways regulated by TF: phagocytosis, immune systems, retina 
homeostasis, neurological process, remodeling of the ECM, mecha-
nisms of cell death, and metabolism. TF up-regulated the expression 
of receptors involved in endocytosis (Cd36, Cd14, and Siglech) and 
down-regulated the expression of vesicle trafficking inhibitors (Tbc1d14, 
Evi5, Tbc1d30, and Usp6nl). As a cargo protein, TF facilitates endocytosis/ 
phagocytosis (27) and vesicle trafficking (28). Among the numerous 
pathways involved in neuroprotection regulated by TF (table S2), the 
IGFBP3 pathway is of particular interest. The up-regulation of IGFBP3 
by TF was confirmed at the protein level, and fig. S8 illustrates IGFBP3 
pathways and the genes in this pathway that were up-regulated (red 
underlined) or down-regulated (green underlined) by TF. The main 
role of IGFBP3 is to regulate the various functions of IGFs (29). 
When iron levels are high, TF forms complexes with IGFBP3 (17), 
preventing binding to its receptors and subsequent apoptosis and 
growth inhibition (29). IGFBP3- TF complex internalization allows 
IGFBP3 to be released to cellular organelles (30) and mediates neuro-
protective effects (see fig. S8 for more details) (29, 31, 32).
From the analysis of ocular fluids of patients with RRD, we have 
demonstrated the oversaturation of TF and iron overload in a hu-
man ocular disease. Despite a high TF concentration in the vitreous, 
iron accumulates in the retina in other human diseases as observed in 
AMD (10); thus, TF oversaturation could be a general mechanism 
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of PR cell death. Therefore, TF supplementation is a credible strategy 
for further translational clinical trials in eligible patients. As com-
pared with other iron chelators, TF treatment not only restores iron 
homeostasis but also activates major neuroprotective pathways such 
as the IGFBP3 pathway. Future work elucidating the iron-unrelated 
pathways of TF will be required. We have used RD as a “model disease” 
in which neuroprotective treatments could show functional endpoints 
in a reasonable time frame. On the basis of the results obtained from ex-
perimental models and from human pathology and because TF is an 
endogenous molecule, clinical studies should be performed to evaluate 
TF in conjunction with RD surgery. Once validated, TF could be 
proposed as a treatment for other diseases associated with RD, such as 
in myopia, or those associated with iron overload such as AMD (10).
MATERIALS AND METHODS
Human samples
Consecutive patients presenting with RRD at Jules-Gonin Eye Hos-
pital (Lausanne, Switzerland) from 1 December 2014 to 31 July 
2015 were included according to the protocol approved by the ethics 
committee and diagnosed through normal standard clinical care at 
first examination. Upon presentation with RRD, the main inclusion 
criterion was the necessity of performing intraocular surgery to limit 
visual impairment in the absence of other ocular conditions. Among 
44 vitreous samples, 35 samples were obtained from patients with 
macula-OFF RD. Nine sex-matched and age-matched patients pre-
sented with macular holes (n = 4) or with epiretinal membranes 
(n = 5), and no other ocular disease were included during the same 
period as control subjects for vitreous humor sampling.
Undiluted vitreous samples were collected by manual aspiration 
through a syringe connected to a 23-gauge vitrectomy cutter (before 
infusion opening; Alcon, Rotkreuz ZG, Switzerland). SRF was col-
lected by active aspiration through a retinal tear (Advanced Back-
flush DSP cannula, Alcon, Rotkreuz ZG, Switzerland). Samples were 
coded and stored in a biobank at −80°C until biochemical analysis.
Duration of RRD (mean: 6.7 ± 5.9 days) was defined as the time 
from the onset of symptoms to surgery. Visual acuities were recorded 
before and 1 month after surgery and converted to the logarithm of 
Fig. 6. Local administration of TF preserves neural retina in the rat model of RD. (A) Rat semithin retinal sections without RD (control) and with RD, treated by either 
intravitreal injection of a control solution [balanced salt solution (BSS)] or TF (50 mg/ml). Retinal histology in the detached area (asterisks) was more preserved in animals 
treated with TF compared with those receiving BSS. Higher magnifications showed less ONL disorganization (arrow) and longer OSs (arrowheads) in TF-treated RD rats. 
Nuclei were stained with toluidine blue. Measurements of thickness in detached retinas were reported relative to undetached retina thickness. (B) Treatment with TF re-
duced thickening of the total retina and the ONL. Mann-Whitney test (n = 5), *P = 0.013 and **P ≤ 0.01. The length of OSs was higher in TF-injected RD rats. Mann-Whitney 
test (n = 5), **P = 0.007. (C) Rhodopsin (green) and arrestin (red) staining in rats 7 days after RD. OSs were preserved in TF-treated animals (arrowhead). Scale bars, 20 m 
(A and C) and 50 m [(A) high magnification]. All values are represented as the mean ± SEM.
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the minimum angle of resolution (LogMAR). Visual recovery was 
defined as the difference between postoperative and preoperative 
LogMAR visual acuity.
Frozen human postmortem eye tissues (10 donors) with non-
hemorrhagic RD retrieved from the pathological files of Jules-Gonin 
Eye Pathology Laboratory were used to stain iron by Perl’s method. 
A block of tissue (1 to 1.5 cm long and 0.5 cm wide) containing the 
RD was processed as serial 5-m-thick paraffin sections.
Animals
Adult male Long-Evans rats (JANVIER LABS, Le Genest St Isle, 
France) (n = 32), adult male Wistar rats (JANVIER LABS) (n = 21), 
adult male C57BL6/J mice (WT) (JANVIER LABS) (n = 40), and 
adult male TG mice expressing human transferrin (TG) (Centre 
d’exploration fonctionnelle du Centre de Recherche des Cordeliers, 
UMRS1138, Paris France) (n = 40) were fed with a standard labora-
tory diet and ad libitum tap water in a room maintained at 21° to 
23°C with a 12-hour light/12-hour dark cycle (6 a.m. to 6 p.m.). 
Mice were anesthetized with an intraperitoneal injection of ket-
amine (80 mg/kg; Virbac, Carros, France) and xylazine (12 mg/kg; 
Bayer, Lyon, France); rats were anesthetized with an intramuscular 
injection of ketamine (35 mg/kg) and xylazine (5 mg/kg). All ani-
mals were sacrificed by carbon dioxide inhalation.
Surgical induction of RD in rodents and study design
Features of retinal degeneration secondary to detachment were ob-
served in animal models in which the retina is mechanically de-
tached by the subretinal injection of sodium hyaluronate. Once 
anesthetized, Long-Evans rats or WT and TG mice received topical 
anesthesia with a drop of 1% tetracaine (Faure, Europhta Laboratories, 
Monaco). Pupil dilatation was achieved by dropwise instillation of 
2 mg/0.4 ml mydriaticum (Théa Laboratories, Clermont-Ferrand, 
France) and 10% phenylephrine hydrochloride (Faure, Europhta 
Laboratories). RD was induced by a subretinal injection of 10 l (mice) 
or 30 l (rats) of sodium hyaluronate (5 mg/ml; Healon, Uppsala, 
Sweden) under an operating microscope using a 34-gauge needle 
through the sclera for a total of 50 animals. The induced RD occu-
pied approximately 30 to 70% of the fundus. Eyes with hemorrhagic 
complications were excluded (nearly 15%). Eyes receiving no injec-
tion were used as controls.
Intravitreal injection in rats was performed immediately after 
RD induction with 5 l of human apoTF solution (50 mg/ml in BSS; 
Sigma-Aldrich, Saint-Quentin en Yvelines, France) or control solu-
tion (BSS), as previously described (12).
Fundus and spectral domain optical coherence tomography were 
simultaneously realized with a Micron III retinal imaging micro-
scope (Phoenix Research Labs, Pleasanton, CA, USA) in anesthetized 
animals as previously described (12) before and after RD induction 
and 4 or 7 days later. At 4 days, some mouse eyes were collected for 
RNA-seq (n = 4 eyes per group). At 7 days, eyes from rats and mice 
were collected for histology and immunostaining (n = 5 and 7 per 
group and per analysis for rats and mice, respectively). At 14 days, rat 
eyes (5 per group) were collected for assay of iron in ocular fluids.
Histology and thickness layer measurement
Fixed eyes were embedded in historesin (Leica, Nanterre, France) to 
facilitate the cutting of 5-m-thick sections through the detached 
area. Sections were stained with 1% toluidine blue solution. Sections 
were observed on a Leitz microscope. Sections with the most de-
tached retinal area were photographed (20×) with a Leica camera 
for measurements (n = 5 WT mice, n = 5 TG mice, n = 5 BSS-treated 
rats, and n = 5 TF-treated rats). Retinal thicknesses [from the OSs to 
the inner part of the ganglion cell layer (GCL) nuclei], the ONL, and 
the outer and inner segments were measured every 100 m (mice) 
and 300 m (rats) using ImageJ software by two different blind ex-
perimenters. Retinas were considered detached when an empty space 
was observed between the RPE and the OSs and attached when any 
signs of histological disturbance were observed. The retinal thick-
ness ratio was calculated as the thickness in the detached retina/the 
thickness in the attached retina. For the ONL and segment thickness 
ratio, layer measurements were reported as the total retinal thickness 
of the corresponding retinal area using the formula (ONL detached/
total retina detached)/(ONL attached/total retina attached).
Immunohistochemistry and fluorescence  
intensity evaluation
Fixed eyes were mounted in Tissue-Tek optimum cutting tempera-
ture (OCT) (Siemens Medical, Puteaux, France) to pass through the 
detached area. Explants were rinsed in 1× phosphate-buffered sa-
line (PBS, Thermo Fisher Scientific, Cergy Pontoise, France), fixed 
for 20 min with 4% paraformaldehyde (Inland Europe, Conflans sur 
Lanterne, France), infiltrated in a sucrose gradient series, and then 
mounted in Tissue-Tek OCT. Immunohistochemistry was performed 
on 10-m-thick sections as previously described (12). Primary anti-
bodies were rabbit polyclonal anti-TFR1 (Serotec, Oxford, UK), rabbit 
polyclonal specific for the light subunit of ferritin (P. Santambrogio), 
rabbit anti-glial fibrillary acid protein (Dako, Thermo Fisher Scientific), 
rabbit anti-ionized calcium-binding adapter molecule 1 (Wako Pure 
Chemical Industries, Neuss, Germany), mouse anti-CD68 (Bio-Rad 
AbD Serotec GmbH, Colmar, France), anti–8-HGN (Abcam, Cambridge, 
UK), anti–4-HNE (Abcam), anti-rhodopsin (Rho4D2, Abcam), anti- 
cone arrestin (Millipore, Saint Quentin En Yvelines, France), and 
anti-IGFBP3 (Santa Cruz Biotechnology). Control sections were in-
cubated with rabbit nonimmune serum (Thermo Fisher Scientific) 
or without primary antibodies. The corresponding Alexa-conjugated 
secondary antibodies (Thermo Fisher Scientific) were used to re-
veal the primary antibodies, and sections were counterstained with 
4,6- diamidino-2-phenylindole (DAPI, Sigma-Aldrich). The TUNEL 
reaction was performed, along with DAPI staining, using the man-
ufacturer’s protocol (Roche Diagnostics, Meylan, France) as pre-
viously described (12). Propidium iodine (0.5 g/ml) was incubated 
directly with sections for 1 hour, and the nuclei were counterstained 
with DAPI.
The sections were photographed with a fluorescence microscope 
(BX51, Olympus, Rungis, France) using identical exposure param-
eters for all compared samples. Blind quantifications were realized 
on photographs acquired at 40× magnification with ImageJ software 
as follows: Quantification of cone nuclei (arrestin staining) or TUNEL- 
positive cells (20× magnifications) in mouse (n = 5 per group) or rat 
(n = 5 per group) models of RD was performed using three photo-
graphs of the attached retina and three photographs of the detached 
retina. Measurement of the OS length in rat retina (n = 5 per group) 
was realized in six photographs by delimiting Rho4D2 staining and 
calculating the mean OS length in each retina area. The OS length 
ratio was then calculated as described for histological measurement. 
For the explant model, all quantifications were performed on four 
photographs (n = 3 explants per group). The OS length measure-
ment was realized by measuring at three equidistant points on the 
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photographs. Fluorescence intensity staining was evaluated on photo-
graphs and reported as the mean intensity under control conditions. 
Each sample measurement was averaged, and differences between 
the groups were analyzed.
Retinal explant cultures
Adult Wistar rat retinas were isolated from fresh enucleated eyes, 
divided into four parts, and transferred to 0.2-mm polycarbonate 
membranes (Millipore) with the GCL facing the membrane (Fig. 2). 
Mouse retinal explants were isolated as indicated above, with one 
explant corresponding to one eye. The insert was placed into a six-
well culture plate containing Dulbecco’s modified Eagle’s medium 
with l-glutamine and 5% serum (Thermo Fisher Scientific) corre-
sponding to day 0. To analyze the effects of iron exposure on retinal 
explants, 30 l of medium containing FeSO4 (7H2O; Sigma-Aldrich) 
was added to the PR side of the explants (upper chamber). To ex-
plore TF’s therapeutic effects, the medium in the upper chamber 
was removed after 2 days. PBS was added for washing, and 30 l of 
medium containing human apoTF (0.5, 5, or 50 mg/ml; Sigma- 
Aldrich) was placed on the retinas. LDH release and enzyme-linked 
immunosorbent assay (ELISA) directed against TF were measured in 
medium collected from the lower chamber as described previously 
(12, 13). Histology, iron staining, immunohistochemistry, and West-
ern blotting were performed on explants as described below and in 
the time workflow legends.
Iron status
Vitreous and SRF samples from humans, ocular fluids from RD rats, 
and medium from rat explants (n = 6 per group) were diluted with 
1% HNO3 solution containing Rh (10 ng/ml) and indium (10 ng/ml) 
as internal standards. In addition, each analytical batch of study 
samples was processed with laboratory controls, including method 
blanks and standard reference materials to continuously monitor 
method performance. Samples were analyzed using an ICP-MS (7700 
Series, Agilent, Santa Clara, CA, USA). Quantitative analysis of iron 
(Fe) was carried out by external calibration using seven standards, 
with concentrations ranging from 10 to 1000 ng/ml. The method 
was assessed using internal and external quality controls, analysis 
of initial calibration, a verification standard, procedural blanks, and 
duplicate samples.
TF and proteins were quantified using an ELISA kit (AssayPro, 
St Charles, USA) and a Micro BCA assay kit (Thermo Fisher Scientific), 
respectively. For human samples, heme iron contamination was 
verified with a hemoglobin colorimetric assay (AssayPro). Saturation 
of TF was calculated as the total iron content (M)/TIBC (M). TIBC 
measures the amount of iron that can potentially be stored in TF 
and corresponds to the capacity of 1 mol of TF (80,000 Da) to bind 
2 mol of ferric iron and was calculated (M) as TF concentration 
(g/liter) × 106 × (2/80,000).
Iron detection staining
Perl’s reaction staining was performed by incubating in a solution con-
taining 4% potassium ferrocyanide (Sigma-Aldrich) in 4% aqueous 
hydrochloric acid (Sigma-Aldrich) for 30 min at room temperature to 
yield a Prussian blue reaction product. Sensitivity for iron detection 
was enhanced by incubation with a solution of 3,3′-diaminobenzidine 
tetrahydrochloride (DAB, 5 mg/ml; Sigma-Aldrich) containing 1% 
H2O2 for 30 min at room temperature. For nucleus counterstaining, in-
cubation with a solution of 1% nuclear red or toluidine blue (Sigma- 
Aldrich) was performed for 30 s. Stained sections were mounted in 
aqueous medium. Control of amplification was realized by incubation 
of sections with DAB without the preceding Perl’s reaction step.
Imaging laser ablation (LA)–ICP-MS measurements were 
performed on a quadrupole instrument (Agilent 7700 ICP series, 
Darmstadt, Germany) hyphenated to a laser ablation system (NWR-
213, New Wave, Fremont, USA) (33). Material on tissue sections 
was ablated by a Nd:YAG/213-nm laser focused at 18 m diameter 
before transport toward the ICP ion source by a helium carrier gas 
with a flow rate of 800 ml/min. The LA-ICP-MS parameters were 
optimized to provide the best signal-to-noise ratio while keeping the 
maximum reproducibility between analyses. In this way, the energy 
output was set at 23%, corresponding to a laser fluency of 0.35 J/cm2. 
The lateral resolution was fixed at 20 m in the raster mode, with a scan 
speed and a repetition frequency of 20 Hz and 20 m/s, respectively. 
56Fe+ was monitored for a duty cycle of 1 s. Raw data were acquired 
using MassHunter software (Agilent, Darmstadt, Germany). Data 
files (.d) of the Imaging MS (IMS) experiments were successively 
converted into mzML and imzML formats using msconvert and 
imzMLConverter tools, respectively. Ion images were reconstructed 
and visualized using the MSIReader v0.06 software.
Western blot analysis
Explants (n = 4 per group) were suspended in lysis MPER buffer 
(Thermo Fisher Scientific) and then centrifuged for 10 min at 4°C. 
Protein concentrations were calculated using the Micro BCA pro-
tein assay (Thermo Fisher Scientific). Five to 10 g of total extract 
was mixed with protein loading buffer (Thermo Fisher Scientific) as 
per the manufacturer’s instructions. Samples were loaded onto 4 to 
12% bis-tris gel (Thermo Fisher Scientific), and proteins were trans-
ferred onto nitrocellulose membranes. Nonspecific binding was 
blocked with 5% nonfat dry milk in Tween/tris-buffered saline, and 
then membranes were incubated overnight at 4°C with the primary 
antibody against rhodopsin (1:5000; ab98887, Abcam), hTF (1:1000; 
ab88165, Abcam), IGFBP3 (clone E9, 1:1,000, Santa Cruz Biotech-
nology), caspase 3 (1:500; clone L-18, Santa Cruz Biotechnology), 
Bcl2 (1:500; clone N-19, Santa Cruz Biotechnology), RIP (1:500; clone 
38, BD Transduction Laboratories), RIP3 (1:1000; PRS2283, Sigma- 
Aldrich), LC3B (1:1000; 2775, Cell Signaling Technology), or actin 
(1:4000; Sigma-Aldrich), followed by incubation with the supplier- 
recommended dilution of horseradish peroxidase–conjugated sec-
ondary antibody for 1 hour (Vector Laboratories, Eurobio, Les Ulis, 
France). Protein bands were visualized by an enhanced chemilumi-
nescence reaction (Thermo Fisher Scientific) using a Bioimaging 
system (MicroChemi 4.2, Berthold, France). The gray values of spe-
cific bands were analyzed using ImageJ, and the protein signals of 
interest were reported relative to the actin signal or to their respec-
tive cleaved forms (for caspase 3 and RIP) for each sample.
Real-time reverse transcription polymerase chain reaction
Neural retinas were isolated on ice and directly frozen until RNA iso-
lation. Tissues were homogenized in tubes prefilled with beads (Bertin 
Technologies, Ozyme, Saint Quentin en Yvelines, France) containing 
RLT lysis buffer (RNeasy mini kit, Qiagen, Courtaboeuf, France) for 
three cycles of 30 s at 5500 rpm in a Precellys Evolution homogenizer 
(Bertin Technologies, Ozyme, Saint Quentin en Yvelines, France). 
Total RNA was isolated with an RNeasy Mini kit (Qiagen, Courtaboeuf, 
France) according to the manufacturer’s protocols. RNA concentra-
tion, purity, and integrity were determined with an Agilent Bioanalyzer. 
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All RNA used had an RNA integrity number (RIN) superior to 8. 
First-strand complementary DNA (cDNA) was generated by reverse 
transcription using 88 ng of total RNA and a QuantiTect Reverse Tran-
scription Kit (Qiagen). Quantitative polymerase chain reaction (PCR) 
using duplicate technical replicates was performed on a Quant Studio 5 
PCR System (Thermo Fisher Scientific) using SYBR Green gene ex-
pression assay probes (QuantiTect Primer Assay, Qiagen) of the mouse 
target genes caspase 8 (Casp8, NM_009812; QT00171437), Igfbp3 
(NM_0008343; QT00493332), an endogenous control actin b (Actb, 
NM_007393; QT01136772), and QuantiFast SYBR Green PCR Master 
Mix (Thermo Fisher Scientific). The expression levels of individual 
genes were normalized with Actb in the same sample by calculation 
of the Ct value, and relative quantification was performed using the 
Ct method with WT retina without DR serving as a control.
RNA sequencing
Retinas (n = 4 per group) were frozen immediately after isolation. 
Total RNA was extracted using a Precellys homogenizer (Ozyme, 
Bertin) and an RNeasy Mini kit (Qiagen). Samples were sent for 
sequencing to the iGenSeq transcriptomic platform of the Brain 
and Spine Institute (Paris, France). The RNA quality was evaluated 
by capillary electrophoresis (Agilent 2100 Bioanalyzer System), and 
RINs ranging from 7.8 to 8.2 were accepted for library generation. 
The cDNA library of each sample was prepared with a KAPA mRNA 
HyperPrep (Roche) for 75–base pair paired-end reads, according to 
the manufacturer’s instructions. Each of the cDNA libraries was in-
dexed for multiplexing (2 × 60 million reads per sample), and in-
dexed libraries were sequenced on one lane of the Illumina NextSeq 
500 device. Data were recorded in the FASTQ format.
RNA-seq data analysis
RNA-seq data analysis was performed by GenoSplice technology 
(www.genosplice.com). Sequencing, data quality, reads repartition 
(e.g., for potential ribosomal contamination), and insert size esti-
mation were performed using FastQC, Picard Tools, SAMtools, and 
RSeQC. Reads were mapped using STAR v2.4.0 on the mm10 mouse 
genome assembly. A gene expression regulation study was performed 
as previously described (34). Briefly, for each gene present in the 
Mouse FAST DB v2016_1 annotations, reads aligning on constitu-
tive regions (that are not prone to alternative splicing) were counted. 
On the basis of these read counts, normalization and differential 
gene expression were performed using DESeq2 on R (v.3.2.5). Only 
genes expressed in at least one of the two compared experimental 
conditions were further analyzed. Genes were considered as ex-
pressed if their reads per kilobase per million mapped reads (RPKM) 
value was greater than 93% of the background RPKM value on the 
basis of intergenic regions. Results were considered statistically 
significant for uncorrected P values ≤0.05 and fold changes ≥1.5 
(GenBank accession number: GSE102824).
Pathway/GO analysis and transcription factor analysis
Clusterings and heat maps were performed on unlabeled data using 
“dist” and “hclust” functions in R, using Euclidean distance and the 
Ward agglomeration method. Analysis for enriched GO terms, 
KEGG pathways, and REACTOME pathways were performed using 
the Database for Annotation, Visualization and Integrated Discovery 
(DAVID) Functional Annotation Tool (v6.8). GO terms and path-
ways were considered enriched if the fold enrichment is ≥2.0, the 
uncorrected P value is ≤0.05, and the minimum number of regulated 
genes in the pathway/term is ≥2.0. Analysis was performed three 
times using all regulated genes, using up-regulated genes, and using 
down-regulated genes only. The union of these three analyses was 
performed to provide a single list of results. Analysis for transcrip-
tion factors was performed using orthologous genes between the 
mouse and the human with the DAVID Functional Annotation 
Tool (v6.8). Orthologous genes are aggregated in FAST DB from 
Ensembl Compara. The same thresholds and methods as GO terms 
and pathway analysis were used but with human data.
Statistical analysis
Results are presented as the mean ± SEM. Analyses were performed 
using GraphPad Prism 5 software. Normal distribution of data 
was confirmed using the Shapiro-Wilk test. Comparisons between 
two groups of human ocular fluid samples were analyzed by an un-
paired two-tailed Student’s t test. Multiple comparisons were per-
formed using one-way analysis of variance (ANOVA) followed by 
the Bonferroni post test as appropriate. Nonnormally distributed 
data were analyzed using a nonparametric Mann-Whitney test to 
compare the two groups. Unadjusted linear regression and two-
tailed Pearson correlation analysis were performed to determine 
whether a relationship existed between iron concentration and delta 
LogMAR visual acuity or RD duration. P < 0.05 was considered sta-
tistically significant.
Study approval
The study involving human subjects adhered to the tenets of the Dec-
laration of Helsinki and was approved by the local ethics committee 
of the Swiss Department of Health on research involving human sub-
jects (CER-VD N°340/15). For vitreous and SRFs, written informed 
consent was obtained from all patients after detailed explanation of 
the purpose and methods of the study. All experimental procedures 
performed using rats and mice were approved by the local ethics 
committee of the Charles Darwin European Council, University of 
Paris-Descartes. Experiments were performed in accordance with 
the Association for Research in Vision and Ophthalmology state-
ment for the use of animals in ophthalmic and vision research.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/1/eaau9940/DC1
Fig. S1. Cell death cellular markers in rat retinal explants exposed to iron.
Fig. S2. TF expression in mouse retinal explants protects from low-serum culturing conditions.
Fig. S3. TF expression in mouse retina explants reduced oxidative stress markers induced by 
iron.
Fig. S4. TF treatment preserves iron-exposed rat retinal explants from oxidative stress and 
inflammation.
Fig. S5. Animal models of RD.
Fig. S6. Iron accumulates in the rodent retina following RD.
Fig. S7. The expression of the TF protein partner, IGFBP3, in mice following RD.
Fig. S8. Proposed role of IGFBP3 in the protective effect of TF.
Table S1. Top 20 up- and down-regulated genes in TG compared with WT mice following RD.
Table S2. Pathways and genes regulated by TF and implicated in PR rescues.
Data file S1. Complete transcriptomic analysis.
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